Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3011MR)

This product GTTS-WQ3011MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7&ITGAE gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000885.6; NM_000889.3; NM_002208.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695; 3682
UniProt ID P13612; P26010; P38570
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3011MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8324MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ7069MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ5056MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ1687MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACZ885
GTTS-WQ10309MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ4349MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ9621MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ488MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW